In patient with cN+ HER2-positive breast cancer when pCR is achieved, 52% of the voters would give trastuzumab and pertuzumab adjuvant treatment of choice regardless of baseline stage, and 32% would favor trastuzumab and pertuzumab but only in baseline stage 3, while 16% would give only trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.